Lantheus price target raised to $141 from $96 at Truist

Truist raised the firm’s price target on Lantheus to $141 from $96 and keeps a Buy rating on the shares. Centers for Medicare & Medicaid Services’ proposed 2025 Hospital Outpatient Prospective Payment, or HOPPS, published on July 10 mitigates the potential for a steep “TPT expiry cliff” for Pylarify, or at least alleviates the weight of the TPT overhang to a large extent, the analyst tells investors in a research note. The firm is also boosting its FY25 EPS view by 80c to $7.74 and its FY26 view by $1.13 to $8.59 following the announcement.